Glioblastoma is a malignant tumor arising from glial cells of the central nervous system, characterized by an aggressive course and a high degree of malignancy. This form of tumor, belonging to the group of gliomas, occupies a special place among primary brain tumors. Glioblastoma is a complex formation consisting of both undifferentiated cells and cells with pronounced cytological atypia. The main feature of this tumor is its ability to quickly invade surrounding tissues, which makes complete surgical removal very difficult. In addition, glioblastomas are often accompanied by significant tissue edema, which worsens the patient's clinical condition.
History of the disease and interesting historical facts
The history of glioblastoma research spans over a hundred years. The tumor was initially described at the beginning of the 20th century, but it was only in the middle of the century that the first clinical data on its characteristics and treatment methods appeared. In the 1950s and 60s, studies began to be conducted on the cell biology of glioblastoma, which led to the recognition of its high aggressiveness and poor prognosis. One of the first systematic approaches to classifying tumors of the central nervous system was the World Health Organization (WHO) system in 1979, which defined glioblastoma as grade IV malignancy. Since then, researchers have focused on studying the molecular mechanisms that lead to the development of glioblastoma, which has opened up new horizons in approaches to its treatment.
Epidemiology
Glioblastoma is the most common and aggressive primary brain tumor. According to various epidemiological studies, the incidence of glioblastoma varies from 3 to 5 cases per 100,000 inhabitants per year. It is more common in men than in women, the ratio is approximately 1.5:1. The age peak of incidence is between 45 and 70 years. Studies show that glioblastoma accounts for about 15% of all primary brain tumors and 60% of all gliomas, which emphasizes its clinical significance and the need for detailed study.
Genetic predisposition to this disease
Glioblastoma is considered a heterogeneous tumor with multiple genetic alterations. The main genes involved in its pathogenesis are TP53, EGFR, PTEN and IDH1. Mutations in the TP53 gene are observed in approximately 30% patients with glioblastoma and are associated with cell cycle dysregulation. Mutations in the EGFR gene, leading to its amplification, are characteristic of this tumor and can promote tumor cell proliferation. In addition, loss of function of the PTEN gene, which is responsible for inhibition of cell proliferation, is also often noted. Studies show that 70% glioblastomas have a less common mutation in the IDH1 gene, which can be used as a molecular marker for early diagnosis of the disease.
Risk factors for the development of this disease
There are several risk factors that may contribute to the development of glioblastoma. These include:
- Age: The incidence increases in people over 45 years of age.
- Gender: Men are at higher risk.
- Pre-existing conditions: Having previous brain tumors may increase your risk.
- Genetic disorders: Certain inherited syndromes (eg, Li-Fraumeni syndrome) increase susceptibility to glioblastoma.
- Radiation: Treating other head and neck tumors with radiation may also increase the risk of developing glioblastoma.
Diagnosis of this disease
Early diagnosis of glioblastoma plays a key role in improving the prognosis. The main symptoms may include:
- Headaches that do not respond to conventional treatment.
- Epileptic seizures of a new type.
- Impaired cognitive function and changes in behavior.
- Limited mobility in the limbs.
- General deterioration of health, fatigue and loss of appetite.
Laboratory tests are generally not able to diagnose glioblastoma, but they can reveal associated diseases. Radiological tests such as magnetic resonance imaging (MRI) and computed tomography (CT) are key in visualizing the tumor and its characteristics. Contrast-enhanced MRI can assess the extent of the tumor and its relationship to surrounding structures. Other tests such as biopsy can provide a tissue sample for histological analysis and confirmation of the diagnosis. Differential diagnosis should be made with other brain tumors such as meningiomas and metastatic tumors.
Treatment
Treatment of glioblastoma typically involves a multidisciplinary approach consisting of surgery, radiation therapy, and chemotherapy. Surgical removal of the tumor is the primary goal, but complete removal may be difficult due to invasive tumor growth into surrounding tissue. Following surgery, radiation therapy may be used to kill any remaining tumor cells, and chemotherapy, most commonly using temozolomide, is given to reduce the risk of recurrence. In recent years, other treatments such as immunotherapy and stem cell-based therapies have been studied and may provide new options for improving treatment outcomes.
List of medications used to treat this disease
- Temozolomide
- Lomustine
- Bevacizumab
- Carboplatin-based therapy
- Procarbazine-based therapy
Disease monitoring
Monitoring of the patient's condition after treatment for glioblastoma includes regular radiological examinations and assessment of clinical symptoms. Control stages are usually performed every three months for the first two years after treatment, and then every six months. The prognosis for glioblastoma remains relatively unfavorable given the aggressive nature of the tumor, with an average survival of 12 to 15 months. It is also important to regularly assess for possible complications, such as disease recurrence, side effects from treatment, and concomitant neurological disorders.
Age-related features of the disease
Glioblastoma has its own characteristics in different age groups. In children and young people, brain tumors, including glioblastoma, are less common, but they can manifest themselves more aggressively and with pronounced neurological symptoms. In older people, glioblastoma can be combined with other diseases, which complicates diagnosis and treatment. In young and middle age, the prognosis is usually worse due to a more aggressive course and pronounced invasiveness of the tumor.
Questions and Answers
- What are the main symptoms of glioblastoma? The main symptoms include headaches, seizures, memory problems and cognitive problems.
- How is glioblastoma diagnosed? Diagnosis includes MRI or CT, biopsy and histological analysis.
- What are the main treatment methods? Treatment includes surgery, radiation therapy and chemotherapy.
- What is the prognosis for glioblastoma? The average survival rate is 12 to 15 months, but much depends on the stage of the disease and the specific treatment.
- Can glioblastoma come back? Yes, recurrences of glioblastoma are quite common.
Advice from Dr. Oleg Korzhikov
When treating glioblastoma, it is important to remember the importance of a comprehensive approach to treatment. Timely diagnosis and an individual treatment program are the determining factors for success. Regular follow-up examinations are necessary to detect relapses in time. In addition, support from loved ones and psychological help can play an important role in the patient's adaptation to new living conditions after treatment. Remember that little-known or new treatment methods require careful discussion with your doctor. Wide awareness of the disease will also help you approach treatment and quality of life issues more effectively.
